Minerva Surgical, Inc. (UTRS)
| Market Cap | 10.39M |
| Revenue (ttm) | 51.69M |
| Net Income (ttm) | -35.55M |
| Shares Out | 8.88M |
| EPS (ttm) | -4.81 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 138,837 |
| Open | 1.57 |
| Previous Close | 1.48 |
| Day's Range | 0.81 - 1.80 |
| 52-Week Range | 0.81 - 14.00 |
| Beta | 0.83 |
| Analysts | Buy |
| Price Target | 20.00 (+1,609.4%) |
| Earnings Date | Nov 13, 2023 |
About UTRS
Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company provides Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure moni... [Read more]
Financial Performance
In 2022, UTRS's revenue was $50.29 million, a decrease of -3.47% compared to the previous year's $52.10 million. Losses were -$34.11 million, 58.9% more than in 2021.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for UTRS stock is "Buy" and the 12-month stock price forecast is $20.0.
News
Minerva Surgical Reports Third Quarter 2023 Financial Results
SANTA CLARA, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uteri...
Minerva Surgical Reports Second Quarter 2023 Financial Results
SANTA CLARA, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uteri...
Minerva Surgical Reports First Quarter 2023 Financial Results
SANTA CLARA, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterin...
Minerva Surgical to Announce First Quarter 2023 Financial Results
SANTA CLARA, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a medical technology company focused on solutions to meet the distinct uterine healthcare needs of women,...
Minerva Surgical Announces the Appointment of Kaile Zagger as Chief Commercial Officer
SANTA CLARA, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical), a women's health company focused on solutions to meet the distinct uterine healthcare ...
Minerva Surgical Reports Fourth Quarter and Full-Year 2022 Financial Results
SANTA CLARA, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a woman's health company focused on solutions to meet the distinct uter...
Minerva Surgical to Announce Fourth Quarter and Full Year 2022 Financial Results
SANTA CLARA, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today tha...
Minerva Surgical Closes $30 Million Private Placement of Common Stock
SANTA CLARA, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a women's health company focused on the treatment of Abnormal Uterine Bl...
Minerva Surgical to Present at the 41st Annual J.P. Morgan Healthcare Conference
SANTA CLARA, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a women's health company focused on the treatment of Abnormal Uterine Bl...
Minerva Surgical Announces Retirement of CEO David Clapper and Appointment of Todd Usen as Company President and CEO
SANTA CLARA, Calif., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a women's health company focused on the treatment of Abnormal Uterine Bl...
Minerva Surgical Announces $30 Million Private Placement of Common Stock Led by Accelmed Partners
SANTA CLARA, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a women's health company focused on the treatment of Abnormal Uterine Bl...
Minerva Surgical to Present at the 34th Annual Piper Sandler Healthcare Conference
SANTA CLARA, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that...
Minerva Surgical Reports Third Quarter 2022 Financial Results
SANTA CLARA, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a woman's health company focused on the treatment of Abnormal Uterine Bl...
Minerva Surgical Announces Change of Date for Third Quarter 2022 Earnings Release and Conference Call
SANTA CLARA, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that...
Minerva Surgical to Announce Third Quarter 2022 Financial Results
SANTA CLARA, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that...
Minerva Surgical to Present at the H.C. Wainwright 24th Annual Global Investment Conference
SANTA CLARA, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a woman's health company focused on the treatment of Abnormal Uterine Bl...
Minerva Surgical Reports Second Quarter 2022 Financial Results
SANTA CLARA, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a woman's health company focused on the treatment of Abnormal Uterine Bl...
Minerva Surgical Announces Time To Talk Campaign
Social Media Campaign and Event Series Encourage Women to Talk Openly About Their Periods Social Media Campaign and Event Series Encourage Women to Talk Openly About Their Periods
Minerva Surgical to Announce Second Quarter 2022 Financial Results
SANTA CLARA, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that...
Minerva Surgical Announces Appointment of Derrick Sung, Ph.D. to Board of Directors
SANTA CLARA, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (“Minerva Surgical” or the “Company”), a woman's health company focused on the treatment of Abnormal Uterin...
Minerva Surgical Reports First Quarter 2022 Financial Results
SANTA CLARA, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a woman's health company focused on the treatment of Abnormal Uterine Ble...
Minerva Surgical to Present at Upcoming Investor Conferences
SANTA CLARA, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that ...
Minerva Surgical to Announce First Quarter 2022 Financial Results
SANTA CLARA, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman's health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today tha...
Minerva Surgical Announces AUB Awareness Day
Minerva calls on women to talk about their periods Minerva calls on women to talk about their periods
Minerva Surgical Reports Fourth Quarter and Full-Year 2021 Financial Results
SANTA CLARA, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a woman's health company focused on the treatment of Abnormal Uterine ...